CN101508713A - Glucoside containing 1,2,3-triazole structure, preparation method and application - Google Patents
Glucoside containing 1,2,3-triazole structure, preparation method and application Download PDFInfo
- Publication number
- CN101508713A CN101508713A CNA2009100682885A CN200910068288A CN101508713A CN 101508713 A CN101508713 A CN 101508713A CN A2009100682885 A CNA2009100682885 A CN A2009100682885A CN 200910068288 A CN200910068288 A CN 200910068288A CN 101508713 A CN101508713 A CN 101508713A
- Authority
- CN
- China
- Prior art keywords
- compound
- methyl
- triazole
- glucopyranoside
- base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention relates to the diabetes-related drug field. More specifically, the invention relates to an sodium glucose transporter 2 (SGLT2) inhibitor containing a 1,2,3-triazolylglucoside structure, a preparation method and application thereof to preparation of antidiabetic drugs, wherein, radicals are defined as in the specification.
Description
Technical field
The present invention relates to the pharmaceutical field relevant with diabetes.Particularly, the present invention relates to contain 1,22 type sodium glucose transporter (SGLT2) inhibitor of 3-triazol radical glucoside structure and preparation method thereof, and the pharmaceutical composition that contains them to diabetes are medicative.
Background technology
Whole world diabetic subject is at present nearly about 1.7 hundred million, mostly approximately is II type (being non-insulin-depending type) diabetic subjects.At present, the conventional medicament of the treatment diabetes of clinical use mainly contains N1,N1-Dimethylbiguanide class, sulfonylurea and trypsin class medicine, and thiazolidinediones medicine, alpha-glucosidase inhibitor and the dipeptidyl peptidase-iv inhibitor etc. of listing in recent years.These medicines have good therapeutic action, but long-term treatment exists such as liver toxicity and weight increase safety issue.
2 type sodium glucose transporters (SGLT2) are the novel targets of the treatment diabetes found this year.The protein of SGLT2 mainly is distributed in kidney, its effect is the glucose that absorbs in the urine, and it is turned back in the blood, the protein target spot that therefore suppresses SGLT2 just can reduce glucose concn in the blood, and this method is different with the approach of the level of in the past lowering blood glucose.Therefore when the SGLT2 function is obstructed, the glucose in the urine will fall by renal secretion more, and this will help the diabetic subject to keep correct glucose level.Because the SGLT2 inhibitor stays out of glucose metabolism, it can be used as the means of supplementing out economy of glycemic control main stream approach.
The invention discloses the New type of S GLT2 inhibitor that can reduce plasma glucose levels effectively, these inhibitor lay the foundation for the medicine that further can be used to prepare diabetes medicament, particularly non insulin dependent diabetes.
Summary of the invention
An object of the present invention is to overcome the shortcoming and defect of prior art, a kind of excellent activity that has is provided, have the compound and the pharmaceutically acceptable ester thereof of general formula I.
Another object of the present invention provides the method that preparation has the compound and the pharmaceutically acceptable ester thereof of general formula I.
A further object of the present invention provide contain general formula I compound as effective constituent, and the medicinal compositions of one or more pharmaceutically acceptable carriers, vehicle or thinner, and the application aspect the treatment diabetes.
Now content of the present invention is specifically described in conjunction with purpose of the present invention.
The compound that the present invention has general formula I has following structural formula:
Wherein,
R
1Be selected from H, F, Cl, Br, I, C
1-C
5Alkyl, CN, NO
2, NR
3R
4And OR
5, and two replacement combination, wherein R of these groups
3And R
4Independently be selected from H and C
1-C
3Alkyl, R
5Be selected from C
1-C
5Alkyl,
R
2Select H and C
1-C
5Alkyl.
Preferred following compound of Formula I or its pharmaceutically acceptable ester,
Wherein,
R
1Be selected from H, F, Cl, C
1-C
3Alkyl, CN, NO
2, NR
3R
4And OR
5, and two replacement combination, wherein R of these groups
3And R
4Independently be selected from H and C
1-C
3Alkyl, R
5Be selected from C
1-C
3Alkyl,
R
2Select H and C
1-C
3Alkyl.
It is as shown in the table that preferred the present invention has the compound and the pharmaceutically acceptable ester thereof of general formula I:
| Compound number | The compound title |
| I-1 | 4-benzyl-1,2,3-triazole-1-base β-D-glucopyranoside |
| I-2 | The 4-[(2-chloro-phenyl-) methyl]-the 5-methyl isophthalic acid, 2,3-triazole-1-base β-D-glucopyranoside |
| I-3 | The 4-[(4-ethylphenyl) methyl]-the 5-methyl isophthalic acid, 2,3-triazole-1-base β-D-glucopyranoside |
| I-4 | The 4-[(4-ethoxyl phenenyl) methyl]-the 5-methyl isophthalic acid, 2,3-triazole-1-base β-D-glucopyranoside |
| I-5 | 5-ethyl-4-[(4-ethylphenyl) methyl]-1,2,3-triazole-1-base β-D-glucopyranoside |
| I-6 | The 4-[(4-ethoxyl phenenyl) methyl]-5-ethyl-1,2,3-triazole-1-base β-D-glucopyranoside |
| I-7 | The 4-[(4-ethylphenyl) methyl]-5-sec.-propyl-1,2,3-triazole-1-base β-D-glucopyranoside |
| I-8 | The 4-[(4-ethoxyl phenenyl) methyl]-5-sec.-propyl-1,2,3-triazole-1-base β-D-glucopyranoside |
| I-9 | The 4-[(4-nitrophenyl) methyl]-5-sec.-propyl-1,2,3-triazole-1-base β-D-glucopyranoside |
| I-10 | The 4-[(3-cyano-phenyl) methyl]-5-sec.-propyl-1,2,3-triazole-1-base β-D-glucopyranoside |
| I-11 | The 4-[(4-dimethylamino phenyl) methyl]-5-sec.-propyl-1,2,3-triazole-1-base β-D-glucopyranoside |
| I-12 | 4-[(2-chloro-4-ethylphenyl) methyl]-5-ethyl-1,2,3-triazole-1-base β-D-glucopyranoside |
| I-13 | The 4-[(4-ethoxyl phenenyl) methyl]-5-sec.-propyl-1,2,3-triazole-1-base 6-O-methoxycarbonyl-β-D-glucopyranoside |
| I-14 | The 4-[(4-ethylphenyl) methyl]-5-sec.-propyl-1,2,3-triazole-1-base 6-O-ethoxycarbonyl-β-D-glucopyranoside |
Compound of Formula I of the present invention is synthetic by following steps:
Compound I I and compound III reaction generate compound IV, and compound IV is reacted under the sodium methylate effect and generated I.Wherein, Compound I I according to literature method preparation (Deng Xiaojuan, Zhou Weiyi, Li Wenbin, 2,3,4,6-is tetra-acetylated-the synthetic and application in liquid chromatography of β-D-glucopyranosyl lsothiocyanates, chemical reagent, 2007,29 (2), 99-10).R
1And R
2Described as defined above.
The pharmaceutically acceptable ester of formula I compound of the present invention comprises the pharmaceutically acceptable ester that the pulsating 6-O of glucose position hydroxyl and ethanoyl in the molecule, propionyl, methoxycarbonyl, benzoyl etc. form.The pharmaceutically acceptable ester of formula I compound prepares with method shown in figure below.
Compound I is with 1 normal R
6COCl handles, and esterification on the pulsating 6-O of Compound I glucose position makes its corresponding ester V.Wherein, R
6Be selected from pharmaceutically acceptable group such as Me, Et, MeO, EtO and Ph, preferred Me, MeO and EtO, more preferably MeO and EtO.
Formula I compound of the present invention or its pharmaceutically acceptable ester can be made pharmaceutical composition jointly with one or more pharmaceutically acceptable carriers, vehicle or thinner.This pharmaceutical composition can be made formulations such as solid orally ingestible, liquid oral medicine, injection.Described solid and liquid oral medicine comprise: tablet, dispersible tablet, enteric coated tablet, chewable tablet, orally disintegrating tablet, capsule, granule, oral solution, described injection preparation comprises injection liquid drugs injection, injection freeze-dried powder, infusion solutions, primary infusion.
Composition of the present invention can be accepted auxiliary material and be selected from: weighting agent, tackiness agent, disintegrating agent, lubricant, glidant, effervescent, correctives, sanitas, coating material or other vehicle on described pharmacy or the bromatology.
Composition of the present invention can be accepted auxiliary material on described pharmacy or the bromatology.Described weighting agent is one or more the composition that comprises lactose, sucrose, dextrin, starch, pregelatinized Starch, N.F,USP MANNITOL, sorbyl alcohol, secondary calcium phosphate, calcium sulfate, lime carbonate, Microcrystalline Cellulose; Described tackiness agent comprises one or more composition of sucrose, starch, polyvidone, Xylo-Mucine, hypromellose, hydroxypropylcellulose, methylcellulose gum, polyoxyethylene glycol, medicinal alcohol, water; Described disintegrating agent comprises one or more composition of starch, crosslinked polyvidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, carmethose, gas-producing disintegrant.
Compound of Formula I of the present invention or its ester have the restraining effect of SGLT2 enzyme, can be used as the medicine that effective constituent is used to prepare the diabetes aspect.The activity of compound of Formula I of the present invention is by hypoglycemic modelling verification in the body.
Compound of Formula I of the present invention is effective in quite wide dosage range.For example the dosage of taking every day is divided into once or administration for several times in 1mg-1000mg/ people's scope.The actual dosage of taking compound of Formula I of the present invention can be decided according to relevant situation by the doctor.These situations comprise: by curer's physical state, route of administration, age, body weight, to the individual reaction of medicine, the severity of symptom etc.
Embodiment
The present invention is further illustrated below in conjunction with embodiment.Need to prove that following embodiment is used for explanation, and is not to be used to limit the present invention.The various variations that those skilled in the art's training centre according to the present invention is made all should be within the desired protection domain of the application's claim.
Embodiment 1
4-benzyl-1,2,3-triazole-1-base β-D-glucopyranoside (I-1)
Add 3.73g (10mmol) Compound I I, 1.16g (10mmol) compound III-1 and 30mL dehydrated alcohol in the round-bottomed flask of a 100mL, reaction mixture temperature rising reflux 12 hours under induction stirring, cooling.Reaction mixture boils off solvent on Rotary Evaporators, resistates obtains the pure product of compound IV-1 through column chromatography purification.The compound IV that obtains-1 is dissolved in the 100mL anhydrous methanol that is dissolved with 0.10g (1.85mmol) solid MeONa in advance, stirred 1 hour under the room temperature, then add 5.0g exsiccant 732 type storng-acid cation exchange resins, stirred 3 hours under the room temperature.Suction filtration is removed resin, and the filtrate evaporate to dryness obtains a white solid, and drying obtains Compound I-1.Clear crystal, 2.73g, productive rate 85%.ESI-MS，m/z＝322([M+H]
+)。
Wherein, compound III-1 and IV-1 are respectively one that has in the compound of general formula III and IV.
Embodiment 2
The 4-[(2-chloro-phenyl-) methyl]-the 5-methyl isophthalic acid, 2,3-triazole-1-base β-D-glucopyranoside (I-2)
Add 3.73g (10mmol) Compound I I, 1.65g (10mmol) compound III-2 and 30mL dehydrated alcohol in the round-bottomed flask of a 100mL, reaction mixture temperature rising reflux 12 hours under induction stirring, cooling.Reaction mixture boils off solvent on Rotary Evaporators, resistates obtains the pure product of compound IV-2 through column chromatography purification.The compound IV that obtains-2 is dissolved in the 100mL anhydrous methanol that is dissolved with 0.10g (1.85mmol) solid MeONa in advance, stirred 1 hour under the room temperature, then add 5.0g exsiccant 732 type storng-acid cation exchange resins, stirred 3 hours under the room temperature.Suction filtration is removed resin, and the filtrate evaporate to dryness obtains a white solid, and drying obtains Compound I-2.Clear crystal, 3.18g, productive rate 86%.ESI-MS，m/z＝370([M+H]
+)。
Wherein, compound III-2 and IV-2 are respectively one that has in the compound of general formula III and IV.
Embodiment 3
The 4-[(4-ethylphenyl) methyl]-the 5-methyl isophthalic acid, 2,3-triazole-1-base β-D-glucopyranoside (I-3)
Add 3.73g (10mmol) Compound I I, 1.58g (10mmol) compound III-3 and 30mL dehydrated alcohol in the round-bottomed flask of a 100mL, reaction mixture temperature rising reflux 12 hours under induction stirring, cooling.Reaction mixture boils off solvent on Rotary Evaporators, resistates obtains the pure product of compound IV-3 through column chromatography purification.The compound IV that obtains-3 is dissolved in the 100mL anhydrous methanol that is dissolved with 0.10g (1.85mmol) solid MeONa in advance, stirred 1 hour under the room temperature, then add 5.0g exsiccant 732 type storng-acid cation exchange resins, stirred 3 hours under the room temperature.Suction filtration is removed resin, and the filtrate evaporate to dryness obtains a white solid, and drying obtains Compound I-3.Clear crystal, 2.94g, productive rate 81%.ESI-MS，m/z＝364([M+H]
+)。
Wherein, compound III-3 and IV-3 are respectively one that has in the compound of general formula III and IV.
Embodiment 4
The 4-[(4-ethoxyl phenenyl) methyl]-the 5-methyl isophthalic acid, 2,3-triazole-1-base β-D-glucopyranoside (I-4)
Add 3.73g (10mmol) Compound I I, 1.74g (10mmol) compound III-4 and 30mL dehydrated alcohol in the round-bottomed flask of a 100mL, reaction mixture temperature rising reflux 12 hours under induction stirring, cooling.Reaction mixture boils off solvent on Rotary Evaporators, resistates obtains the pure product of compound IV-4 through column chromatography purification.The compound IV that obtains-4 is dissolved in the 100mL anhydrous methanol that is dissolved with 0.10g (1.85mmol) solid MeONa in advance, stirred 1 hour under the room temperature, then add 5.0g exsiccant 732 type storng-acid cation exchange resins, stirred 3 hours under the room temperature.Suction filtration is removed resin, and the filtrate evaporate to dryness obtains a white solid, and drying obtains Compound I-4.Clear crystal, 3.03g, productive rate 80%.ESI-MS，m/z＝380([M+H]
+)。
Wherein, compound III-4 and IV-4 are respectively one that has in the compound of general formula III and IV.
Embodiment 5
5-ethyl-4-[(4-ethylphenyl) methyl]-1,2,3-triazole-1-base β-D-glucopyranoside (I-5)
Add 3.73g (10mmol) Compound I I, 1.72g (10mmol) compound III-5 and 30mL dehydrated alcohol in the round-bottomed flask of a 100mL, reaction mixture temperature rising reflux 12 hours under induction stirring, cooling.Reaction mixture boils off solvent on Rotary Evaporators, resistates obtains the pure product of compound IV-5 through column chromatography purification.The compound IV that obtains-5 is dissolved in the 100mL anhydrous methanol that is dissolved with 0.10g (1.85mmol) solid MeONa in advance, stirred 1 hour under the room temperature, then add 5.0g exsiccant 732 type storng-acid cation exchange resins, stirred 3 hours under the room temperature.Suction filtration is removed resin, and the filtrate evaporate to dryness obtains a white solid, and drying obtains Compound I-5.Clear crystal, 3.20g, productive rate 85%.ESI-MS，m/z＝378([M+H]
+)。
Wherein, compound III-5 and IV-5 are respectively one that has in the compound of general formula III and IV.
Embodiment 6
The 4-[(4-ethoxyl phenenyl) methyl]-5-ethyl-1,2,3-triazole-1-base β-D-glucopyranoside (I-6)
Add 3.73g (10mmol) Compound I I, 1.88g (10mmol) compound III-6 and 30mL dehydrated alcohol in the round-bottomed flask of a 100mL, reaction mixture temperature rising reflux 12 hours under induction stirring, cooling.Reaction mixture boils off solvent on Rotary Evaporators, resistates obtains the pure product of compound IV-6 through column chromatography purification.The compound IV that obtains-6 is dissolved in the 100mL anhydrous methanol that is dissolved with 0.10g (1.85mmol) solid MeONa in advance, stirred 1 hour under the room temperature, then add 5.0g exsiccant 732 type storng-acid cation exchange resins, stirred 3 hours under the room temperature.Suction filtration is removed resin, and the filtrate evaporate to dryness obtains a white solid, and drying obtains Compound I-6.Clear crystal, 3.42g, productive rate 87%.ESI-MS，m/z＝394([M+H]
+)。
Wherein, compound III-6 and IV-6 are respectively one that has in the compound of general formula III and IV.
Embodiment 7
The 4-[(4-ethylphenyl) methyl]-5-sec.-propyl-1,2,3-triazole-1-base β-D-glucopyranoside (I-7)
Add 3.73g (10mmol) Compound I I, 1.86g (10mmol) compound III-7 and 30mL dehydrated alcohol in the round-bottomed flask of a 100mL, reaction mixture temperature rising reflux 12 hours under induction stirring, cooling.Reaction mixture boils off solvent on Rotary Evaporators, resistates obtains the pure product of compound IV-7 through column chromatography purification.The compound IV that obtains-7 is dissolved in the 100mL anhydrous methanol that is dissolved with 0.10g (1.85mmol) solid MeONa in advance, stirred 1 hour under the room temperature, then add 5.0g exsiccant 732 type storng-acid cation exchange resins, stirred 3 hours under the room temperature.Suction filtration is removed resin, and the filtrate evaporate to dryness obtains a white solid, and drying obtains Compound I-7.Clear crystal, 3.32g, productive rate 85%.ESI-MS，m/z＝392([M+H]
+)。
Wherein, compound III-7 and IV-7 are respectively one that has in the compound of general formula III and IV.
Embodiment 8
The 4-[(4-ethoxyl phenenyl) methyl]-5-sec.-propyl-1,2,3-triazole-1-base β-D-glucopyranoside (I-8)
Add 3.73g (10mmol) Compound I I, 2.02g (10mmol) compound III-8 and 30mL dehydrated alcohol in the round-bottomed flask of a 100mL, reaction mixture temperature rising reflux 12 hours under induction stirring, cooling.Reaction mixture boils off solvent on Rotary Evaporators, resistates obtains the pure product of compound IV-8 through column chromatography purification.The compound IV that obtains-8 is dissolved in the 100mL anhydrous methanol that is dissolved with 0.10g (1.85mmol) solid MeONa in advance, stirred 1 hour under the room temperature, then add 5.0g exsiccant 732 type storng-acid cation exchange resins, stirred 3 hours under the room temperature.Suction filtration is removed resin, and the filtrate evaporate to dryness obtains a white solid, and drying obtains Compound I-8.Clear crystal, 3.62g, productive rate 89%.ESI-MS，m/z＝408([M+H]
+)。
Wherein, compound III-8 and IV-8 are respectively one that has in the compound of general formula III and IV.
Embodiment 9
The 4-[(4-nitrophenyl) methyl]-5-sec.-propyl-1,2,3-triazole-1-base β-D-glucopyranoside (I-9)
Add 3.73g (10mmol) Compound I I, 2.03g (10mmol) compound III-9 and 30mL dehydrated alcohol in the round-bottomed flask of a 100mL, reaction mixture temperature rising reflux 12 hours under induction stirring, cooling.Reaction mixture boils off solvent on Rotary Evaporators, resistates obtains the pure product of compound IV-9 through column chromatography purification.The compound IV that obtains-9 is dissolved in the 100mL anhydrous methanol that is dissolved with 0.10g (1.85mmol) solid MeONa in advance, stirred 1 hour under the room temperature, then add 5.0g exsiccant 732 type storng-acid cation exchange resins, stirred 3 hours under the room temperature.Suction filtration is removed resin, and the filtrate evaporate to dryness obtains a white solid, and drying obtains Compound I-9.Clear crystal, 3.71g, productive rate 91%.ESI-MS，m/z＝409([M+H]
+)。
Wherein, compound III-9 and IV-9 are respectively one that has in the compound of general formula III and IV.
Embodiment 10
The 4-[(3-cyano-phenyl) methyl]-5-sec.-propyl-1,2,3-triazole-1-base β-D-glucopyranoside (I-10)
Add 3.73g (10mmol) Compound I I, 1.83g (10mmol) compound III-10 and 30mL dehydrated alcohol in the round-bottomed flask of a 100mL, reaction mixture temperature rising reflux 12 hours under induction stirring, cooling.Reaction mixture boils off solvent on Rotary Evaporators, resistates obtains the pure product of compound IV-10 through column chromatography purification.The compound IV that obtains-10 is dissolved in the 100mL anhydrous methanol that is dissolved with 0.10g (1.85mmol) solid MeONa in advance, stirred 1 hour under the room temperature, then add 5.0g exsiccant 732 type storng-acid cation exchange resins, stirred 3 hours under the room temperature.Suction filtration is removed resin, and the filtrate evaporate to dryness obtains a white solid, and drying obtains Compound I-10.Clear crystal, 3.49g, productive rate 90%.ESI-MS，m/z＝389([M+H]
+)。
Wherein, compound III-10 and IV-10 are respectively one that has in the compound of general formula III and IV.
Embodiment 11
The 4-[(4-dimethylamino phenyl) methyl]-5-sec.-propyl-1,2,3-triazole-1-base β-D-glucopyranoside (I-11)
Add 3.73g (10mmol) Compound I I, 2.01g (10mmol) compound III-11 and 30mL dehydrated alcohol in the round-bottomed flask of a 100mL, reaction mixture temperature rising reflux 12 hours under induction stirring, cooling.Reaction mixture boils off solvent on Rotary Evaporators, resistates obtains the pure product of compound IV-11 through column chromatography purification.The compound IV that obtains-11 is dissolved in the 100mL anhydrous methanol that is dissolved with 0.10g (1.85mmol) solid MeONa in advance, stirred 1 hour under the room temperature, then add 5.0g exsiccant 732 type storng-acid cation exchange resins, stirred 3 hours under the room temperature.Suction filtration is removed resin, and the filtrate evaporate to dryness obtains a white solid, and drying obtains Compound I-11.Clear crystal, 3.65g, productive rate 90%.ESI-MS，m/z＝407([M+H]
+)。
Wherein, compound III-11 and IV-11 are respectively one that has in the compound of general formula III and IV.
Embodiment 12
4-[(2-chloro-4-ethylphenyl) methyl]-5-ethyl-1,2,3-triazole-1-base β-D-glucopyranoside (I-12)
Add 3.73g (10mmol) Compound I I, 2.21g (10mmol) compound III-12 and 30mL dehydrated alcohol in the round-bottomed flask of a 100mL, reaction mixture temperature rising reflux 12 hours under induction stirring, cooling.Reaction mixture boils off solvent on Rotary Evaporators, resistates obtains the pure product of compound IV-12 through column chromatography purification.The compound IV that obtains-12 is dissolved in the 100mL anhydrous methanol that is dissolved with 0.10g (1.85mmol) solid MeONa in advance, stirred 1 hour under the room temperature, then add 5.0g exsiccant 732 type storng-acid cation exchange resins, stirred 3 hours under the room temperature.Suction filtration is removed resin, and the filtrate evaporate to dryness obtains a white solid, and drying obtains Compound I-12.Clear crystal, 4.05g, productive rate 95%.ESI-MS，m/z＝426([M+H]
+)。
Wherein, compound III-12 and IV-12 are respectively one that has in the compound of general formula III and IV.
Embodiment 13
The 4-[(4-ethoxyl phenenyl) methyl]-5-sec.-propyl-1,2,3-triazole-1-base 6-O-methoxycarbonyl-β-D-glucopyranoside (I-13)
Add 4.07g (10mmol) Compound I-8,1.01g (10mmol) triethylamine and 30mL exsiccant methylene dichloride in the round-bottomed flask of a 50mL, flask is cooled off and induction stirring with mixture of ice and water, slowly drip 0.95g (10mmol) methyl-chloroformate and be dissolved in the solution of making in the 2mL dry methylene chloride, after dropwising, reaction mixture at room temperature stirs and spends the night.Reaction system with the water washing of 100mL saturated common salt once, is used anhydrous sodium sulfate drying with the dilution of 150mL methylene dichloride, boils off solvent on Rotary Evaporators, and the resistates that obtains obtains the pure product of Compound I-13 through column chromatography purification.Clear crystal, 4.28g, productive rate 92%.ESI-MS，m/z＝466([M+H]
+)。
Embodiment 14
The 4-[(4-ethylphenyl) methyl]-5-sec.-propyl-1,2,3-triazole-1-base 6-O-ethoxycarbonyl-β-D-glucopyranoside (I-14)
Add 3.91g (10mmol) Compound I-7,1.01g (10mmol) triethylamine and 30mL exsiccant methylene dichloride in the round-bottomed flask of a 50mL, flask is cooled off and induction stirring with mixture of ice and water, slowly drip 1.09g (10mmol) Vinyl chloroformate and be dissolved in the solution of making in the 2mL dry methylene chloride, after dropwising, reaction mixture at room temperature stirs and spends the night.Reaction system with the water washing of 100mL saturated common salt once, is used anhydrous sodium sulfate drying with the dilution of 150mL methylene dichloride, boils off solvent on Rotary Evaporators, and the resistates that obtains obtains the pure product of Compound I-14 through column chromatography purification.Clear crystal, 4.17g, productive rate 90%.ESI-MS，m/z＝464([M+H]
+)。
Embodiment 15
Consumption/sheet
Embodiment 1 sample (I-1) 100mg
Microcrystalline Cellulose 80mg
Pregelatinized Starch 70mg
Polyvinylpyrrolidone 6mg
Carboxymethyl starch sodium salt 5mg
Magnesium Stearate 2mg
Talcum powder 2mg
Activeconstituents, pregelatinized Starch and Microcrystalline Cellulose are sieved, thorough mixing, add polyvinylpyrrolidonesolution solution, mix, the system softwood, sieve, the system wet granular is in 50-60 ℃ of drying, with the carboxymethyl starch sodium salt, Magnesium Stearate and talcum powder sieve in advance, join compressing tablet in the above-mentioned particle then.
Embodiment 16
Consumption/sheet
Embodiment 3 samples (I-3) 100mg
Microcrystalline Cellulose 80mg
Pregelatinized Starch 70mg
Polyvinylpyrrolidone 6mg
Carboxymethyl starch sodium salt 5mg
Magnesium Stearate 2mg
Talcum powder 2mg
Activeconstituents, pregelatinized Starch and Microcrystalline Cellulose are sieved, thorough mixing, add polyvinylpyrrolidonesolution solution, mix, the system softwood, sieve, the system wet granular is in 50-60 ℃ of drying, with the carboxymethyl starch sodium salt, Magnesium Stearate and talcum powder sieve in advance, join compressing tablet in the above-mentioned particle then.
Embodiment 17
Consumption/grain
Embodiment 4 samples (I-4) 50mg
Microcrystalline Cellulose 30mg
Pregelatinized Starch 20mg
Polyvinylpyrrolidone 3mg
Magnesium Stearate 2mg
Talcum powder 1mg
Activeconstituents, pregelatinized Starch and Microcrystalline Cellulose are sieved, and thorough mixing adds polyvinylpyrrolidonesolution solution, mixes, the system softwood sieves, and the system wet granular is in 50-60 ℃ of drying, Magnesium Stearate and talcum powder are sieved in advance, join then in the above-mentioned particle, encapsulated, promptly.
Embodiment 18
Consumption/grain
Embodiment 6 samples (I-6) 50mg
Microcrystalline Cellulose 30mg
Pregelatinized Starch 20mg
Polyvinylpyrrolidone 3mg
Magnesium Stearate 2mg
Talcum powder 1mg
Activeconstituents, pregelatinized Starch and Microcrystalline Cellulose are sieved, and thorough mixing adds polyvinylpyrrolidonesolution solution, mixes, the system softwood sieves, and the system wet granular is in 50-60 ℃ of drying, Magnesium Stearate and talcum powder are sieved in advance, join then in the above-mentioned particle, encapsulated, promptly.
Embodiment 19
Consumption/50mL
Embodiment 7 samples (I-7) 50mg
Citric acid 100mg
NaOH an amount of (transferring pH4.0-5.0)
Distilled water 50mL
In distilled water, add earlier distilled water and citric acid, stirring and dissolving and after, add sample again, low-grade fever makes dissolving, and adjust pH is 4.0-5.0, add 0.2 gram activated carbon, stirred 20 minutes under the room temperature, filter filtrate, strength of solution is decided in middle detection, by 5 milliliters of packing of every peace bottle, high-temperature sterilization 30 minutes promptly gets injection liquid.
Embodiment 20
Consumption/50mL
Embodiment 8 samples (I-8) 50mg
Citric acid 100mg
NaOH an amount of (transferring pH4.0-5.0)
Distilled water 50mL
In distilled water, add earlier distilled water and citric acid, stirring and dissolving and after, add sample again, low-grade fever makes dissolving, and adjust pH is 4.0-5.0, add 0.2 gram activated carbon, stirred 20 minutes under the room temperature, filter filtrate, strength of solution is decided in middle detection, by 5 milliliters of packing of every peace bottle, high-temperature sterilization 30 minutes promptly gets injection liquid.
Embodiment 21
Embodiment 12 samples (I-12) 3.0g
Poloxamer 1.0g
Sodium hydroxide 0.2g
Citric Acid QS
N.F,USP MANNITOL 26.0g
Lactose 23.0g
Water for injection 100ml
Preparation technology: get water for injection 80ml, add main ingredient, N.F,USP MANNITOL, lactose, poloxamer stir make dissolving after, the Citric Acid that adds 1mol/L is regulated PH to 7.0-9.0, mends and adds water to 100ml.Add the 0.5g gac, stirred 20 minutes down, take off charcoal, adopt the filtering with microporous membrane degerming at 30 ℃, filtrate is carried out packing by every 1ml, and pre-freeze is after 2 hours, freezing drying under reduced pressure down 12 hours, to sample temperature after room temperature, dry 5 hours again, make the white loose block, seal promptly.
Embodiment 22
100 bags of granules
Embodiment 13 samples (I-13) 30.0g
Lactose 55.0g
N.F,USP MANNITOL 14.0g
The sweet 0.05g of A Siba
Essence 0.05g
2% hypromellose (pure water preparation) QS
Preparation technology: main ingredient and auxiliary material are crossed 100 mesh sieves respectively, and thorough mixing takes by weighing recipe quantity auxiliary material and main ingredient thorough mixing then.Add tackiness agent system softwood again, 14 mesh sieves are granulated, 55 ℃ of dryings, and the whole grain of 12 mesh sieves is measured heavily packing of bag.
Embodiment 23
Sample is mixed with the suspension of 5mg/mL concentration with 1% Xylo-Mucine, and the administration capacity is the 0.4mL/20g body weight, is equivalent to 100mg/kg dosage.
Healthy ICR mouse, male and female half and half, body weight 20-24g meets primary standard.Animal fasting 16 hours, the dextrose in saline solution of 2h abdominal injection 2g/kg behind the medicine (1.5h injectable dextrose monohydrate behind the gliclazide medicine), 0.5h, 1h, 2h, 3h and 4h regularly take kapillary and get blood from mouse ball rear vein beard after modeling, centrifugation serum is with each time point serum glucose level of determination of glucose oxidase.The results are shown in following table:
Above result shows that each administration all can significantly reduce the mouse blood sugar dosis tolerata that glucose causes.
Claims (10)
1. have the compound of general formula I structure and acceptable ester pharmaceutically thereof
Wherein,
R
1Be selected from H, F, Cl, Br, I, C
1-C
5Alkyl, CN, NO
2, NR
3R
4And OR
5, and two replacement combination, wherein R of these groups
3And R
4Independently be selected from H and C
1-C
3Alkyl, R
5Be selected from C
1-C
5Alkyl,
R
2Select H and C
1-C
5Alkyl.
2. claim 1 is defined has the compound of general formula I and an acceptable ester pharmaceutically thereof
Wherein,
R
1Be selected from H, F, Cl, C
1-C
3Alkyl, CN, NO
2, NR
3R
4And OR
5, and two replacement combination, wherein R of these groups
3And R
4Independently be selected from H and C
1-C
3Alkyl, R
5Be selected from C
1-C
3Alkyl,
R
2Select H and C
1-C
3Alkyl.
3. the defined compound of Formula I of claim 2 and pharmaceutically acceptable ester are selected from:
4-benzyl-1,2,3-triazole-1-base β-D-glucopyranoside
The 4-[(2-chloro-phenyl-) methyl]-the 5-methyl isophthalic acid, 2,3-triazole-1-base β-D-glucopyranoside
The 4-[(4-ethylphenyl) methyl]-the 5-methyl isophthalic acid, 2,3-triazole-1-base β-D-glucopyranoside
The 4-[(4-ethoxyl phenenyl) methyl]-the 5-methyl isophthalic acid, 2,3-triazole-1-base β-D-glucopyranoside
5-ethyl-4-[(4-ethylphenyl) methyl]-1,2,3-triazole-1-base β-D-glucopyranoside
The 4-[(4-ethoxyl phenenyl) methyl]-5-ethyl-1,2,3-triazole-1-base β-D-glucopyranoside
The 4-[(4-ethylphenyl) methyl]-5-sec.-propyl-1,2,3-triazole-1-base β-D-glucopyranoside
The 4-[(4-ethoxyl phenenyl) methyl]-5-sec.-propyl-1,2,3-triazole-1-base β-D-glucopyranoside
The 4-[(4-nitrophenyl) methyl]-5-sec.-propyl-1,2,3-triazole-1-base β-D-glucopyranoside
The 4-[(3-cyano-phenyl) methyl]-5-sec.-propyl-1,2,3-triazole-1-base β-D-glucopyranoside
The 4-[(4-dimethylamino phenyl) methyl]-5-sec.-propyl-1,2,3-triazole-1-base β-D-glucopyranoside
4-[(2-chloro-4-ethylphenyl) methyl]-5-ethyl-1,2,3-triazole-1-base β-D-glucopyranoside
The 4-[(4-ethoxyl phenenyl) methyl]-5-sec.-propyl-1,2,3-triazole-1-base 6-O-methoxycarbonyl-β-D-glucopyranoside
The 4-[(4-ethylphenyl) methyl]-5-sec.-propyl-1,2,3-triazole-1-base 6-O-ethoxycarbonyl-β-D-glucopyranoside.
4. synthesize the method for the defined compound of Formula I of claim 1-3, may further comprise the steps:
Compound I I and compound III reaction generate compound IV, and compound IV is reacted under the sodium methylate effect and generated I.R
1And R
2Described as defined above.
5. the synthetic defined compound of Formula I of claim 1-3 is the step of acceptable ester pharmaceutically,
Compound I is with 1 normal R
6COCl handles, and esterification on the pulsating 6-O of Compound I glucose position makes the pharmaceutically acceptable ester of the desired I of this claim 1-3.Wherein, R
6Be selected from pharmaceutically acceptable group such as Me, Et, MeO, EtO and Ph, preferred Me, MeO and EtO, more preferably MeO and EtO.
6. the defined compound of Formula I of claim 1-3 is as the application of 2 type sodium glucose transporter inhibitor.
7. the application of the defined compound of Formula I of claim 1-3 aspect preparation treatment diabetes medicament.
8. pharmaceutical composition contains compound of Formula I and appropriate carriers or the vehicle of one of claim 1-3.
9. the described pharmaceutical composition of claim 8, wherein, described composition is solid orally ingestible, liquid oral medicine or injection.
10. comprise according to described solid of claim 9 and liquid oral medicine: tablet, dispersible tablet, enteric coated tablet, chewable tablet, orally disintegrating tablet, capsule, granule, oral solution, described injection preparation comprises injection liquid drugs injection, injection freeze-dried powder, infusion solutions, primary infusion.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2009100682885A CN101508713A (en) | 2009-03-30 | 2009-03-30 | Glucoside containing 1,2,3-triazole structure, preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2009100682885A CN101508713A (en) | 2009-03-30 | 2009-03-30 | Glucoside containing 1,2,3-triazole structure, preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101508713A true CN101508713A (en) | 2009-08-19 |
Family
ID=41001257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2009100682885A Pending CN101508713A (en) | 2009-03-30 | 2009-03-30 | Glucoside containing 1,2,3-triazole structure, preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101508713A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108752404A (en) * | 2018-07-03 | 2018-11-06 | 山东省科学院生物研究所 | A kind of berberine salt derivative and its preparation method and application that triazole is sugar-modified |
| CN111205344A (en) * | 2020-01-14 | 2020-05-29 | 华东理工大学 | Pure organic phosphorescent small-molecule material for methanol solvent recognition and preparation method thereof |
-
2009
- 2009-03-30 CN CNA2009100682885A patent/CN101508713A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108752404A (en) * | 2018-07-03 | 2018-11-06 | 山东省科学院生物研究所 | A kind of berberine salt derivative and its preparation method and application that triazole is sugar-modified |
| CN111205344A (en) * | 2020-01-14 | 2020-05-29 | 华东理工大学 | Pure organic phosphorescent small-molecule material for methanol solvent recognition and preparation method thereof |
| CN111205344B (en) * | 2020-01-14 | 2023-03-14 | 华东理工大学 | Pure organic phosphorescent small-molecule material for methanol solvent recognition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102134226B (en) | Phenyl C-glucoside derivatives, preparation method and use thereof | |
| CN101508712A (en) | Glucoside containing tetrazole structure, preparation method and application | |
| CN101445527A (en) | Five-membered heteroaromatics tolylene glucoside and preparation method and use thereof | |
| CN103864737A (en) | Phenyl C-glucoside derivative containing deoxyglucose structure as well as preparation method and application thereof | |
| CN101157692A (en) | Berberinc derivatives, preparation method and medicinal composition and usage thereof | |
| CN103788043A (en) | Crystal form IV of nicousamide compound as well as preparation method, drug composition and application thereof | |
| CN101445528B (en) | Sulpho-glucosan derivative and preparation method and application thereof | |
| CN101508713A (en) | Glucoside containing 1,2,3-triazole structure, preparation method and application | |
| US7662364B2 (en) | Drug for hyperphospheremia and its preparative method | |
| CN101463055B (en) | O-indican compounds, preparation and use thereof | |
| CN103570657A (en) | Phenyl-glucoside derivative containing gem-dimethyl, preparation method and use thereof | |
| CN101550112B (en) | 4,5-disubstituted thiazole derivative, preparation method and use thereof | |
| CN102408459B (en) | Anomeric alkyl-containing phenyl C-glucoside derivative, preparation thereof and application | |
| CN101715448A (en) | The therapeutic uses of imidazol-5-carboxylic acid derivatives | |
| CN102675378A (en) | C-glucoside derivative containing cyclopropane structure and method and application of C- glucoside derivative | |
| CN101684103B (en) | Compound with 1,2,4-triazole structure and preparation method and application thereof | |
| CN109288836A (en) | A kind of dihydralazine sulfate,clonidine and hydrochlorothiazine preparation and its preparation method and application | |
| CN101805336B (en) | Compound containing tryptophane and isoxazole skeleton and preparation method and application thereof | |
| CN101805308B (en) | Compound containing tyrosine and isoxazole skeleton and preparation method and application thereof | |
| CN101684088B (en) | Cyanomethyl pyrrole derivative and preparation method and application thereof | |
| CN101696228A (en) | N-pyrazolyl glycosides derivatives as well as preparation method and application thereof | |
| CN101955502A (en) | thiogalactosiTtderivatives, preparation method and application thereof | |
| CN110551088B (en) | Deuterium-modified benzyl-4-chlorophenyl C-glycoside derivatives | |
| CN111195247B (en) | Alpha-glucosidase inhibitor and application thereof in hypoglycemic drugs | |
| CN114984004B (en) | Application of sulbactam sulfate in preparation of anti-sepsis medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20090819 |